

April 25, 2017



## **Poxel Announces Appointment of Anne Renevot as Chief Financial Officer**

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs for metabolic disorders, including type 2 diabetes, announced today that Anne Renevot has joined Poxel and will serve in a senior leadership role as Chief Financial Officer (CFO).

“We are very pleased to welcome Anne, a seasoned financial executive, who has held a series of senior financial roles at public and private companies. Anne brings with her over 25 years of experience and a wide range of financial capabilities, including private and public equity financings, strategic and operational planning, and regulatory compliance for publicly-listed companies,” said Thomas Kuhn, CEO of Poxel. “Anne is joining us at a pivotal time as we prepare for Imeglimin’s Phase 3 registration program for the treatment of diabetes in Japan and plan to further leverage our internal capabilities to advance additional programs in the metabolic area.”

“I am delighted to join the talented team at Poxel at such an exciting time for the Company,” said Anne Renevot, CFO of Poxel. “Poxel has a strong track record of raising capital and advancing its programs, and I look forward to helping the Company in its endeavor to develop new innovative therapies to treat patients with diabetes and other metabolic disorders.”

Prior to joining Poxel, Anne Renevot served as CFO of EOS Imaging where she played a key role in EOS’ successful IPO on Euronext Paris, which raised €39M. At EOS Imaging, Ms. Renevot helped to raise capital through private placements, equity lines and debt offerings. She was responsible for financial regulatory compliance, financial planning and communications, and she also held leading roles in the Company’s acquisitions and partnerships. Before her appointment at EOS Imaging, Ms. Renevot served at Cartier, a luxury goods company, as CFO of Cartier Joaillerie Manufacturing Division and as International Financial Controller. Earlier in her career, Ms. Renevot served as Manager at EY Audit and as a Division Controller at Legris Industries.

Anne Renevot received a bachelor’s degree in finance from Audencia Business School in Nantes, France and a master’s degree in corporate finance from Ohio State University, Columbus, Ohio.

### **About Poxel**

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes. We

have successfully completed our Phase 2 clinical program for our first-in-class lead clinical candidate, Imeglimin, which targets mitochondrial dysfunction for the treatment of diabetes, in the U.S. and EU and have fully enrolled a Phase 2b clinical study in Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, [www.poxel.com](http://www.poxel.com))

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20170424006108/en/>

**Poxel SA**

Jonae R. Barnes, +1 617-818-2985

Senior Vice President, Investor Relations and Public Relations

[jonae.barnes@poxelpharma.com](mailto:jonae.barnes@poxelpharma.com)

or

**Investor relations / Media - EU/US**

MacDougall Biomedical Communications

Gretchen Schweitzer or Stephanie May

+ 49 89 2424 3494 or + 49 175 571 1562

[smay@macbiocom.com](mailto:smay@macbiocom.com)

or

**Investor relations / Media - France**

NewCap

Florent Alba/Nicolas Mériegeau

+ 33 1 44 71 98 55

[poxel@newcap.fr](mailto:poxel@newcap.fr)

Source: POXEL SA